Figure 1.

Med potentiates TRAIL-induced apoptosis in leukemia cells. (a) Chemical structure of Med. (b) K562, LAMA-84, U937, and OCIAML-3 cells were treated with indicated doses of Med for 48 h. Cell viability was then analyzed by cytotoxicity assay using CCK-8 as described under ‘Materials and Methods'. (c) K562, LAMA-84, U937, and OCIAML-3 cells were treated with indicated doses of TRAIL for indicated time points and cell viability was then analyzed by cytotoxicity assay using CCK-8 as described under ‘Materials and Methods'. (d) K562, LAMA-84, U937, and OCIAML-3 cells were treated with 20 μM Med and indicated doses of TRAIL for 48 h. Cell viability was then analyzed by cytotoxicity assay using CCK-8 as described under ‘Materials and Methods'. (e) K562, LAMA-84, U937 and OCIAML-3 cells were treated with 20 μM Med and indicated doses of TRAIL for 48 h. Released LDH was measured as described under ‘Materials and Methods'. Data are presented as mean±S.D. of three independent experiments. *P>0.05, **P>0.001, ***P>0.0001 in treated groups versus control group